Skip to main content
SpringerLink
Log in

Aspirin not worth risks for primary CVD prevention

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK.Effect of Aspirin on Vascular and Nonvascular Outcomes - Meta-analysis of Randomized Controlled Trials. Archives of Internal Medicine: [8 pages], 9 Jan 2012. Available from: URL: http://dx.doi.org/10.1001/archinternmed.2011.628

  2. Mayor S.Risks of aspirin outweigh benefits in people without cardiovascular disease, shows analysis. BMJ 344: e241, 9 Jan 2012. Available from: URL: http://dx.doi.org/10.1136/bmj.e241

  3. Mora S.Aspirin Therapy in Primary Prevention: To Use or Not to Use? Archives of Internal Medicine: [3 pages], 9 Jan 2012. Available from: URL: http://dx.doi.org/10.1001/archinternmed.2011.626

  4. De Jong PTVM, Chakravarthy U, Rahu M, Seland J, Soubrane G, Topouzis F, Vingerling JR, Vioque J, Young I, Fletcher AE.Associations between Aspirin Use and Aging Macula Disorder - The European Eye Study. Ophthalmology 119: 112-118, Jan 2012

    Google Scholar 

  5. American Academy of Ophthalmology.New Study Links Daily Aspirin Use to Increased Risk of Age-Related Macular Degeneration. Media Release: 3 Jan 2012. Available from: URL: http://www.aao.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aspirin not worth risks for primary CVD prevention. React. Wkly. 1385, 3 (2012). https://doi.org/10.2165/00128415-201213850-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213850-00005

Keywords

Search

Navigation